IMP: A New Paradigm – clinical trials seminar

Published: 2-May-2014 Featured companies: PCI Pharma Services
Regulatory Research & Development

PCI presents the latest in its Global Clinical Trail Service seminar series

In today’s dynamically changing environment, innovation and cost efficiency in drug development is crucial; the drug development timeline is under constant attack and speed to market is paramount to success.

Packaging Coordinators, Inc (PCI) invites you to a complimentary breakfast seminar you can’t afford to miss. The latest in the company's Global Clinical Trail Service seminar series will be held on 18 June at the Holiday Inn, Oxford, OX2 8JD, UK.

Join us to learn how to deal with challenging timelines and discover new and innovative routes to market.

Register now at http://pciservices.com/uk-oxford-seminar-june-2014/ or by emailing becky.griffiths@pciservices.com.

Featured companies

PCI Pharma Services: Your bridge between life-changing therapies and patients.
See more

You may also like

Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

Read more
This financial injection is expected to cement PCI’s position in the CDMO arena

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA

Relevant companies

See more

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Strategic investment by Bain Capital, Kohlberg and Mubadala fuels PCI Pharma Services’ expansion

This financial injection is expected to cement PCI’s position in the CDMO arena
Distribution

CDMO PCI Pharma Services wins a US Supply Chain Excellence Award

The company was acknowledged for its digital clinical trial and commercial lifespan management solution, pci I bridge
Manufacturing

PCI Pharma becomes first CDMO to complete an ICRMA site inspection

The ICMRA's pilot scheme aims to accelerate the regulatory approval process for pharmaceutical companies
Manufacturing

Aldena Therapeutics selects PCI Pharma Services to manufacture and distribute innovative investigational treatment for dermatological diseases

World-leading CDMO offers highly specialised experience bringing complex formulations to market quickly and will support clinical trials of Aldena's siRNA-based injectable treatment
Research & Development

Manufacturing Chemist Live: Day Two Review

At the close of MCL’s second and final day, attendees have once again had the chance to enjoy engaging, interesting and above all, useful presentations from experts across the industry
Manufacturing

Big names announced for leading Pharma and Cleanroom conference

The Cleanroom Technology Conference and Manufacturing Chemist Live collaboration will take place on the 10-11 November. Delegate tickets are currently available
Manufacturing

PCI and Experic announce strategic drug supply chain collaboration

Complementary technologies and capabilities add value and drive growth for both companies
Subscribe now